General Information of Drug (ID: DMJFPK6)

Drug Name
CIGB-228 Drug Info
Synonyms Therapeutic peptide subunit vaccine (E7 antigen, HPV), CIGB
Indication
Disease Entry ICD 11 Status REF
Human papillomavirus infection 1A9Y Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMJFPK6

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
VGX-3100 DMMQ2U9 Cervical Intraepithelial neoplasia 2E66.1 Phase 3 [2]
Tipapkinogene sovacivec DM5XRMA Cervical Intraepithelial neoplasia 2E66.1 Phase 2 [3]
ADXS-HPV DMC8NAO Cervical cancer 2C77.0 Phase 2 [4]
KITE-439 DMUB3H9 Cervical cancer 2C77.0 Phase 1 [5]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Human papillomavirus protein E7 (HPV E7) TT3CPZW VE7_HPV16 Not Available [1]

References

1 Safety and Immunogenicity of a Human Papillomavirus Peptide Vaccine (CIGB-228) in Women with High-Grade Cervical Intraepithelial Neoplasia: First-in-Human, Proof-of-Concept Trial. ISRN Obstet Gynecol. 2011; 2011: 292951.
2 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
3 Immune therapy for human papillomaviruses-related cancers
4 ADXS11-001 immunotherapy targeting HPV-E7: updated survival and safety data from a phase 2 study in Indian women with recurrent/refractory cervical cancer. Journal for ImmunoTherapy of Cancer, 2013, 1(Suppl 1):P231.
5 ClinicalTrials.gov (NCT03912831) Safety and Efficacy of KITE-439 in HLA-A*02:01+ Adults With Relapsed/Refractory HPV16+ Cancers. U.S. National Institutes of Health.